Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GNX-5086
- Development stage
- Unknown
- Lead developer
- Genextra
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
GNX-5086 is a potent small molecule inhibitor of the mitochondrial permeability transition pore (mPTP), developed by Congenia S.r.l. (a subsidiary of Genextra SpA). It is designed to mitigate cardiac reperfusion injury (RI) in patients undergoing percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI). By inhibiting the mPTP, GNX-5086 increases the capacity of mitochondria to retain calcium, thereby protecting them from calcium overload and subsequent cell death during the restoration of blood flow. The drug has been evaluated in a Phase I clinical trial for safety, tolerability, and pharmacokinetics in healthy volunteers.
02
Targets
MPTP (Mitochondrial permeability transition pore)
Beyond the preview
Go deeper on GNX-5086.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GNX-5086.